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Abstract 
HIV-1 resistance to antiretroviral therapy (ART) is a crucial issue, despite various effective drugs are available 
for the treatment.  Although the viral RNA is suppressed below the detection limit (<50 copies/ml) with the use 
of potent antiviral drugs, the mutation can be archived in the cellular reservoir as proviral DNA. The detection 
of proviral DNA and mutation screening in HIV 1 RNA for genotypic resistance is the sole basis for monitoring 
the effectiveness of ART. Our study aim to access the extent of latent HIV infections by detecting env V3 DNA 
and also testing of M184V (meth184val; ATG - GTG substitution at 184th codon) specific mutations in HIV-1 RT 
gene to monitor the effectiveness of ART. The HIV-1 env V3 DNA sequence was amplified using multiple 
upstream and downstream primes to show the latent HIV infections, whereas polymerase chain reaction- 
restriction fragment digestion assay (PCR-RFDA) was used for testing M184V mutation in HIV-1 RT gene. In the 
study, out of 15 HIV infected patient blood samples, 12 shows amplification of env V3 DNA, confirming the latent 
HIV infections while 3 were negative for env V3 DNA. HIV-1 RT gene tested for M184V mutation in all 15 samples 
showed wild type after analysis using PCR-RFDA. After digestion with CviAII, three bands were observed in 
wild type whereas in mutant only two bands. Although the study shows negative for the M184V resistance 
mutation, screening of various panels of drug resistance mutations should be performed in recently infected HIV-
1 patients for planning the effective ART strategy. The data is not enough to compare the overall scenario of the 
Nepal thus warrant urgency for large scale study with standard genotypic tools. 
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Introduction 
HIV/AIDS is the gradually increasing global 
epidemic threat with an estimated 36.7 million HIV 
positive people worldwide. Among them 5.1 
million people are in Asia including 3,00,000 newly 
infected and 1,80,000 AIDS-related deaths occurred 
in Asia per year [1]. Till date 39,249 people are 
estimated to be living with HIV in Nepal [2]. 
The HIV epidemic has changed due to use of  
antiretroviral therapies (ARTs) that suppress the 
HIV-1 RNA load in plasma below the detection limit 
(<50 copies/ml). However, lifelong ART is 
necessary for patients with latent HIV infections 
due to decrease in level of CD4+ lymphocytes [3, 4]. 
The decrease in level of CD4+ T cells caused by HIV 
infection leads into AIDS and cause opportunistic 
infections, like Pneumocystis Carinii pneumonia 
and Kaposi’s sarcoma [5]. More than 50% of the 
worldwide epidemic are due to HIV-1 subtype C 
and are prone to genotypic resistance with 
treatment failure. HIV-1 has a higher rate of 
replication with lack of 3’ to 5’ proof reading 
mechanism and highly error-prone to reverse 
transcriptase [6-8]. The selection of drug specific 
resistance mutation in viral genome is due to 
treatment failure and those mutations may be 
archived into the cellular reservoir (Proviral DNA). 
Thus, mutations can be detected in proviral DNA 
even if HIV RNA is below detection limit [9].  HIV-
1 resistance to ART is a major problem which is due 
to suboptimum treatment and transmission of 
resistant variant at the time of infection [10-12]. 
Resistance mutation is associated with high 
replicative activities of the viral genome during 
therapy. Several drugs have been approved for the 
treatment of HIV-1 infection such as nucleotide and 
nucleoside reverse transcriptase inhibitors (NRTIs), 
protease inhibitors (PIs), nonnucleoside RT 
inhibitors (NNRTIs), and fusion inhibitors. 
However, drug resistance mutations in HIV-1 
remain crucial, even though effective (ART) is 
available in the global market. One of the commonly 
associated drug resistance mutations in HIV-1 RT 
gene is M184V. The appearance of Lamivudine 
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(3TC) resistance mutation, M184I, was found to be 
transiently proceeded to the outgrowth of M184V 
substitution [13-15]. The study of the nucleotide 
sequences of both 3TC-resistant variants shows that 
M184V (GTG) originates from wild-type Met (ATG) 
but not from the M184I variant (ATA) [16]. Both 
variants are generated from the wildtype ATG 
sequence by transitional substitutions (G to A for 
184I and A to G for 184V). The G to A substitution is 
the type of mutation that most commonly occur 
during replication of HIV-1 thus M184I appears 
before M184V [17, 18]. In addition, there have been 
no systematic studies of HIV-1 resistance mutation 
in Nepalese population. 
Here, we performed the preliminary study of 
common drug resistance mutation, M184V using a 
basic molecular tool called PCR-RFDA and assessed 
the detection of proviral DNA in HIV-1 infected 
patients with prolonged ART. 
Materials and Methods 
Patients counselling and collection of 
samples 
Individual patient counselling was performed on 
the background of HIV/AIDs, diagnosis, 
monitoring, treatment, drug resistant and genotype 
testing. A questionnaire was performed with 
regards to drug use, sexual behavior and travel 
history. 15 samples were collected from HIV-1 
infected patients undergoing long term ART 
commonly with 2-3 NRTIs and 1-2 PIs or an NNRTI 
for at least 3 - 4 years recruited in sparsha Nepal, 
sanepa, Kathmandu was included. Out of 15 cases, 
only two were clinically approved as ART resistance 
and viral loads of each patients are shown in Table 
1. Data were collected as a part of a continuing study 
of antiretroviral treatment at the time of primary 
HIV-1 infection, which was approved by the 
Department of Laboratory Medicine, Research 
Committee of Nobel College and Chief of Sparsha 
Nepal.  
Extraction of Nucleic Acid 
The nucleic acid extraction procedure was 
performed in Biosafety cabinet (BSL-2). HIV-1 RNA 
was extracted using precision QIAamp Viral RNA 
mini kit (Qiagen, Hilden, Germany) while DNA was 
extracted using Shine Gene Whole Blood DNA 
extraction kit (Wuhe Road, Minhang District, 
Shanghai, China) as per manufacturer's 
instructions. 
Proviral DNA Detection: Nested PCR 
Nested PCR for HIV-1 env gene 
The nested PCR was performed in the env V3 DNA 
sequences of HIV-1 for the amplification using high-
fidelity Pfu DNA Polymerase. The amplification 
was performed as described in previous study [19]. 
The total reaction volume of 20μl containing 1X PCR 
buffer, 1.5 mM MgCl2, 200 μM dNTPs, and 0.25 U 
of Pfu enzyme and RNase free water. The first 
round PCR was performed with 0.5 μM of upstream 
primers JA9AE (5’-
CACAGTACAATGCACACATG-3’), JA9B (5’-
CACAGTACAATGTACACATG-3’), and 
downstream primers JA12A (5’-
GCAATAGAAAAATTCTCCTC-3’), JA12B (5’-
ACAGTAGAAAAATTCCCCTC-3’). The reaction 
mixture was incubated at 95°C for 15 minutes, 94°C 
for 30 Sec, 58°C for 30 Sec, 72°C for 30 Sec and 72°C 
for 10 minutes, for 35 PCR cycles. 1 μl of the first-
round PCR product was used as template for 
second-round PCR. Inner upstream primers used 
were a mixture of 0.33 μM each of JA10UB (5’-
CTGTTAAATGGCAGTCTAGC-3’), JA10UC (5’-
CTGTTAAATGGTAGTCTAGC-3’), and JA10UG 
(5’-CTGTTAAATGGCAGTTTAGC-3’). Inner 
downstream primers used were different for each 
reaction, namely, 0.33 μM each of JA11LAE (5’-
AATTTCTAGATCCCCTCCTG-3’), JA11LB (5’-
AATTTCTGGGTCCCCTCCTG-3’), and JA11LC (5’-
AATTTCTAGGTCCCCTCCTG-3’). The reaction 
mixture was incubated at 95°C for 15 minutes, 94°C 
for 30 Sec, 50°C for 30 Sec, 72°C for 30 Sec and 72°C 
for 10 minutes, for 35 PCR cycles. The final PCR 
product was resolved in 1.7% agarose gel 
electrophoresis and image was captured using gel 
documentation. 
HIV-1 RNA Mutational (M184V) 
Analysis: PCR-RFDA 
RT gene amplification: Nested PCR 
The amplification of HIV-1 RT gene was performed 
using nested primer pairs which were reported in 
previous study [20]. The isolated HIV-1 RNA was 
subjected to OneStep RT-PCR (Qiagen, Hilden, 
Germany). The RT-PCR product was then used as 
templates for second round PCR. The QIAGEN  
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OneStep RT-PCR was performed as recommended 
by the manufacturer. The total volume of 50μl 
reaction was carried out containing RNase free 
water, 1x OneStep RT-PCR buffer, 200 μM dNTP 
mix, 0.6 μM of each primers A1 (5’-
AATTTTCCCATTAGCCCTATT-3’) and NE1 (5’-
TATGTCATTGACAGTCCAGCT-3’), 2μl of 
OneStep RT-PCR enzyme mix, 5 units RNase 
inhibitor and 2 μg viral RNA for reverse-
transcriptase gene. The reaction was incubated at 
48°C for 20 minutes (reverse transcription) followed 
by 94°C for 4 minutes, 94°C for 30 Sec, 52°C for 30 
Sec, 72°C for 30 Sec, and 72°C for 10 minutes, for 35 
PCR cycles. The second round PCR was done by 
using a QIAGEN master mix with 5 µl of the first 
RT-PCR product and primers NNA (5’-
AAGCCAGGAATGGATGGCCCA-3,) and E (5’-
CCATTTATCAGGATGGAGTTC-3’). The reaction 
mixture was incubated at 95°C for 15 minutes, 94°C 
for 30 Sec, 50°C for 30 Sec, 72°C for 45 Sec and 72°C 
for 10 minutes, for 30 PCR cycles.  
M184V Mutation Testing: Restriction 
Fragment Digestion Assay (RFDA) 
The amplified RT gene was tested for M184V 
mutation by digestion approach called RFDA. The 
RFDA was performed using restriction enzymes 
CviAII. The total volume of 50μl reaction was 
performed containing 1X NEBuffer, 10 units’ CviAII 
restriction enzyme, and 1μg RT-PCR product at 
25oC for 1 hour. The digested product was resolved 
in 1.7% agarose gel electrophoresis and image were 
captured using gel documentation. 
Results 
In the present study, detection of proviral DNA by 
amplification of env V3 DNA sequences was done by 
nested PCR while testing of resistance mutation in 
the HIV-1 RT (MET 184 VAL) gene was performed 
by PCR and RFDA. Individual band, resulting from 
final PCR product and enzyme digested product 
was compared with ART resistance strain and 
molecular size marker (100bp). The results are 
tabulated and is shown in Table 1. 
Table 1: Patient’s information, ART and genotypic testing in the study population n-15 
Code Gender/Age ART used Viral Load 
copies/ml 
env V3 DNA M184V Mutation Patient Status 
HRM1 Male/36 yrs AZT, 3TC, NFV 1500 Positive Negative Critical 
HRM2 Male/33 yrs AZT, 3TC, EFZ 1500 Positive Negative Critical 
HRM3 Male/26yrs AZT, 3TC, NFV 1500 Positive Negative Critical 
HRM4 Male/35yrs AZT, 3TC, NFV 1000 Positive Negative Expired 
HRM5 Male/23yrs AZT, 3TC, NFV 1000 Positive Negative ART 
HRM6 Male/32yrs AZT, 3TC, NFV 300 Negative Negative ART 
HRM7 Male/34yrs AZT, 3TC, NFV 800 Positive Negative ART 
HRM8 Male/25yrs AZT, 3TC, NFV 800 Positive Negative ART 
HRM9 Male/28yrs AZT, 3TC, EFZ 500 Positive Negative ART 
HRM10 Male/30yrs AZT, 3TC, NFV 250 Negative Negative ART 
HRM11 Male/36yrs AZT, 3TC, NFV 300 Negative Negative ART 
HRM12 Male/25yrs AZT, 3TC, NFV 750 Positive Negative ART 
HRM13 Male/27yrs AZT, 3TC, NFV 400 Positive Negative ART 
HRM14 Female/28yrs AZT, 3TC, EFZ 650 Positive Negative ART 
HRM15 Female/33yrs AZT, 3TC, NFV 550 Positive Negative ART 
Key: HRM-HIV-1 Resistance Mutation, ART-Anti Retroviral Therapy, AZT- Zidovudine, 3TC- Lamivudine, EFV-Efavirenz, NFV- 
Nelfinavir 
Table 2: Most common mutations in RT gene and specific drugs resistance. 
Resistance genes Resistance level 
Mutation Gene High Intermediate Low 
M184V/I RT 3TC,  FTC - ABC, ddI 
K65R RT ABC, ddI, TNF, d4T 3TC, FTC  
M41L RT AZT, d4T ddI, ABC TNF 
K103N RT EFV, NVP - - 
Key: 3TC- Lamivudine, FTC-emtricitabine, AZT- Zidovudine, d4T- Stavudine, EFV-Efavirenz, NVP- Nevirapine, ABC- Abacavir, ddI- 
Didanosine, TNF- Tenofovir  
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Identification of env V3 DNA 
The env V3 DNA sequence was analyzed to rule out 
latent HIV-1 infections. Out of 15 samples amplified 
for env gene, only 12 of samples show positive for 
env V3 DNA sequence by nested PCR. The size of 
the product was 335bp which was a band of our  
Figure 1: Nested PCR for env V3 DNA sequences. Marker (M) of 100bp was used to compare the molecular weight of 
amplified product resolved in gel of 1.7%. a) Amplified product with band of interest (335bp) was visualized in all lane 
1-6. b) Amplified product was observed only in lane 7, 8, 10, 12 but not in lane 9 and 11.  Gel image of 3 positive samples 
is not shown.
interest and is illustrated in Figure 1 (a & b). The 
remaining 3 samples negative for the same gene was 
reamplified twice showed the similar results. The 
reason for env gene negative in those three samples 
might be due to complete elimination of proviral 
DNA or due to its reduction below the detection 
limit after prolonged ART. 
M184V mutation in HIV-1 RT gene 
HIV-1 RNA was tested for the most common 
mutation; M184V which emerges in patients using 
lamivudine (3TC) monotherapy or can be a 
phenotypic reversion of zidovudine (ZDV). PCR-
RFDA molecular tool was used for testing the 
mutation in which gene was amplified by nested 
PCR and further final product was digested with 
CviAII restriction endonucleases. In the present 
study, we tested M184V mutation in 15 samples and 
all showed wildtype strain. The wildtype strains 
show three fragment after digestion with band size 
of 453bp, 60bp and 168bp  are susceptible to 3TC 
while mutant type have 2 bands with size of 453bp 
and 228bp are considered as 3TC  resistance which 
means the M184V resistance mutation was emerged 
by modification of the 184 restriction site 
substituting CviAII enzymes. The virtual schematic 
illustration of Nested PCR and RFDA of both wild 
type and mutant type is shown in Figure 2 (a & b). 
Discussion 
Early detection of drug resistance mutation in 
HIV-1 infected patients in developing countries is 
a big challenge however, can aid clinicians in 
making proper ART strategy plans. Various 
molecular tools like real time PCR and sequencing 
facilities are still lacking. Also, such tools are 
expensive and less sensitive to minor resistance 
variants. The development of cheap and sensitive 
tools to screen resistance mutation can be a 
breakthrough in the field of molecular biology for 
low economic countries like Nepal. In the study, 
we used nested PCR and PCR-RFDA to detect 
HIV-1 Infections and screen the prevalence of 
M184V mutation in HIV-1 patients underwent 
prolong ART. The cheap and sensitive methods 
for detecting primary infection in infants and 
latent HIV-1 infection is to identify proviral DNA. 
The HIV proviral DNA is positive after 28 days 
while most healthy individuals are accustomed to 
waiting 3 months for a conclusive result. We 
performed nested PCR to identify the env V3 DNA 
sequences in 15 samples, out of which 12 showed 
positive for proviral DNA. The PCR amplification 
on 3 negative samples was repeated twice with the 
same primers for the env V3 DNA but consistently 
the results were negative. The reason might be a 
low copy number which is below the detection 
limit or can be complete elimination of proviral 
DNA due to prolonged ART. The standard 
methods for the detection of HIV-1 Proviral DNA 
are currently lacking and several discordant 
results are still present in different studies [21]. In 
the present study, we didn’t study for the 
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Figure 2: Nested PCR and RFDA for detection of M184V resistance mutation. a) Wildtype stain with three bands of 
size 453bp, 60bp, 168bp. b) Mutant strain with two bands of size 453bp and 228bp 
resistance mutation in HIV-1 proviral DNA. 
However, the presence of drug resistance 
mutations in the reservoir of latent HIV-1 provirus 
and their stability may impact future management 
and/or treatment possibilities.  The presence of 
latent proviral DNA doesn’t indicate the 
resistance to ART but the specific mutation like 
M184V, k65R, M41L and K103N etc. can be 
 detected if the similar mutation is observed in 
HIV-1 RNA. This is due to retention of 
mutant from HIV-1 RNA into cDNA due to long 
term suppressive ART that integrates into host 
genome. The evolution of drug resistance mutation 
in globally epidemic HIV-1 is due to suboptimal 
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treatment, a point mutation in viral genome and 
resistance variants leads to incomplete suppression 
of the viral genome. The development of drug 
resistance mutation threatens the success of the 
future therapy regimens. The challenge in treatment 
of HIV-1 is associated with the development of drug 
resistance mutation against antiretroviral drugs 
which can significantly reduce the viral RNA to 
undetectable levels in plasma [22]. The various 
resistance mutation pattern has been reported with 
majorities in both nucleoside reverse transcriptase 
inhibitors (NRTIs) and non- nucleoside reverse 
transcriptase inhibitors (NNRTIs) while only a few 
with NNRTIs and also in minor ratio with protease 
inhibitors (PI) and 3- class resistance (NRTIs, 
NNRTIs and PIs). The genotyping of the reverse 
transcriptase gene sequence revealed that almost 
90% resistance mutation were M184V [23] and such 
mutation emerges in patients receiving lamivudine 
(3TC) therapy, but also it could be associated with 
phenotypic reversion of zidovudine (ZDV) 
resistance [24]. In the present study, we screened for 
M184V resistance mutation in HIV-1 infected 
patients receiving 3TC in combination by PCR-
RFDA methods. The only wild type strain was 
found in all the sample analyzed which means the 
M184V mutation was negative. Our results 
completely contradict the other reports on M184V. 
In the study though phenotypic resistance and high 
viral load were included, M184V mutation was not 
detected which might be due to numerous reasons 
like 1) duration of 3TC ART, 2) Possibilities of other 
mutation like M184I, K65R, etc  3) change in drugs  
4) less likely to be technical error .  The commonly 
used drugs by the HIV-1 infected patients in Nepal 
are AZT, 3TC, EFV and NFV and is shown in Table 
1. The high level resistance to 3TC associated with 
M184V mutation is also resistance to other drugs 
like FTC, ABC and ddI. In addition to this, resistance 
to 3TC is also associated with K65R mutation and its 
variant forms but the level of resistance may vary 
from high-intermediate-low. The most common RT 
gene mutation and specific drug resistance is shown 
in Table 2. There are several mutations in genes of 
HIV-1 associated with resistance to specific drugs 
[25]. The M184V mutation was detected in lesser 
than 10% by allele specific PCR but was consistently 
negative by standard genotyping [26] While the 
ratio of mutant and wild type is equal to 50:50 
reported by almost half of the laboratories [27]. The 
prevalence of the M184V mutation is notably higher 
than that of other mutation [28-30] and is 
significantly associated with 3TC [31].  
The early detection of resistance mutation in HIV-1 
infected patients would help to change the 
treatment regimens susceptible to both Proviral 
DNA and viral RNA and control measures can be 
taken to minimize the transmission of resistant 
variants. An understanding of the molecular 
mechanism of drug resistance will enable us to 
develop improved tools for resistance screening.  
Conclusion 
In the present study, we set out to identify the HIV-
1 latent infections by detecting env V3 DNA 
sequences using nested PCR. In addition to this, the 
M184V resistance mutation was not observed in the 
samples analyzed thus indicating as wild type 
strain. Also, we optimized the PCR-RFDA protocol 
using CviAII restriction enzymes for the HIV-1 RT 
strains for mutation testing. This strategy was 
meant to enhance assay discrimination between the 
specific drug resistance mutation (mutant allele) 
and its wild type (wild type allele) using nested 
primers and CviAII restriction enzymes.  
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